Literature DB >> 8875228

A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction.

J R Dorin1, R Farley, S Webb, S N Smith, E Farini, S J Delaney, B J Wainwright, E W Alton, D J Porteous.   

Abstract

Quantifying the level of transgene expression necessary for phenotypic effect is an important consideration in designing somatic gene therapy protocols. A nonlinear relationship between phenotype and gene activity is predicted by control analysis for any autosomal recessive condition. The unaffected phenotype of heterozygotes for autosomal recessive disorders demonstrates that 50% of the normal level of gene expression is sufficient to prevent disease. By extension, an exaggerated and positive effect on the mutant phenotype is predicted to arise from only a small addition of normal transgene expression delivered by gene therapy. We tested this expectation directly by intercrossing mice carrying different Cftr alleles which modulate Cftr gene expression from 0 to 100%. We demonstrate that 5% of the normal level of Cftr gene expression results in a disproportionately large correction of the chloride ion transport defect (50% of normal) and essentially complete rescue of the intestinal disease (100% survival). It follows that even modest levels of transgene expression and only partial correction of CFTR channel activity may have a significant clinical impact.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8875228

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  35 in total

Review 1.  New therapeutic approaches for cystic fibrosis lung disease.

Authors:  Jane C Davies
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

2.  Optimization of hCFTR lung expression in mice using DNA nanoparticles.

Authors:  Linas Padegimas; Tomasz H Kowalczyk; Sam Adams; Chris R Gedeon; Sharon M Oette; Karla Dines; Susannah L Hyatt; Ozge Sesenoglu-Laird; Olena Tyr; Robert C Moen; Mark J Cooper
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

Review 3.  Genetics and pulmonary medicine. 1. The genetics of cystic fibrosis lung disease.

Authors:  D J Davidson; D J Porteous
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

Review 4.  Gene therapy for cystic fibrosis: which postman, which box?

Authors:  P G Middleton; E W Alton
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

5.  Transcriptional targeting in the airway using novel gene regulatory elements.

Authors:  Erin R Burnight; Guoshun Wang; Paul B McCray; Patrick L Sinn
Journal:  Am J Respir Cell Mol Biol       Date:  2012-03-23       Impact factor: 6.914

6.  Processing and function of CFTR-DeltaF508 are species-dependent.

Authors:  Lynda S Ostedgaard; Christopher S Rogers; Qian Dong; Christoph O Randak; Daniel W Vermeer; Tatiana Rokhlina; Philip H Karp; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-14       Impact factor: 11.205

7.  A truncated CFTR protein rescues endogenous DeltaF508-CFTR and corrects chloride transport in mice.

Authors:  Estelle Cormet-Boyaka; Jeong S Hong; Bakhram K Berdiev; James A Fortenberry; Jessica Rennolds; J P Clancy; Dale J Benos; Prosper N Boyaka; Eric J Sorscher
Journal:  FASEB J       Date:  2009-07-20       Impact factor: 5.191

8.  High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors.

Authors:  Manij Patel; Angela M Giddings; John Sechelski; John C Olsen
Journal:  J Gene Med       Date:  2013-01       Impact factor: 4.565

9.  Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs.

Authors:  David A Stoltz; Tatiana Rokhlina; Sarah E Ernst; Alejandro A Pezzulo; Lynda S Ostedgaard; Philip H Karp; Melissa S Samuel; Leah R Reznikov; Michael V Rector; Nicholas D Gansemer; Drake C Bouzek; Mahmoud H Abou Alaiwa; Mark J Hoegger; Paula S Ludwig; Peter J Taft; Tanner J Wallen; Christine Wohlford-Lenane; James D McMenimen; Jeng-Haur Chen; Katrina L Bogan; Ryan J Adam; Emma E Hornick; George A Nelson; Eric A Hoffman; Eugene H Chang; Joseph Zabner; Paul B McCray; Randall S Prather; David K Meyerholz; Michael J Welsh
Journal:  J Clin Invest       Date:  2013-05-08       Impact factor: 14.808

10.  In vitro and in vivo functional characterization of gutless recombinant SV40-derived CFTR vectors.

Authors:  C Mueller; M S Strayer; J Sirninger; S Braag; F Branco; J-P Louboutin; T R Flotte; D S Strayer
Journal:  Gene Ther       Date:  2009-11-05       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.